Primary ciliary dyskinesia

Recent advances in diagnostics, genetics, and characterization of clinical disease

Michael R. Knowles, Leigh Anne Daniels, Stephanie Davis, Maimoona A. Zariwala, Margaret W. Leigh

Research output: Contribution to journalArticle

199 Citations (Scopus)

Abstract

Primary ciliary dyskinesia (PCD) is a genetically heterogeneous recessive disorder of motile cilia that leads to oto-sino-pulmonary diseases and organ laterality defects in approximately 50% of cases. The estimated incidence of PCD is approximately 1 per 15,000 births, but the prevalence of PCD is difficult to determine, primarily because of limitations in diagnostic methods that focus on testing ciliary ultrastructure and function. Diagnostic capabilities have recently benefitted from (1) documentation of low nasal nitric oxide production in PCD and (2) discovery of biallelic mutations in multiple PCD-causing genes. The use of these complementary diagnostic approaches shows that at least 30% of patients with PCD have normal ciliary ultrastructure. More accurate identification of patients with PCD has also allowed definition of a strong clinical phenotype, which includes neonatal respiratory distress in >80% of cases, daily nasal congestion and wet cough starting soon after birth, and early development of recurrent/chronic middle-ear and sinus disease. Recent studies, using advanced imaging and pulmonary physiologic assessments, clearly demonstrate early onset of lung disease in PCD, with abnormal air flow mechanics by age 6-8 years that is similar to cystic fibrosis, and age-dependent onset of bronchiectasis. The treatment ofPCDis not standardized, and there are no validated PCD-specific therapies. Most patients with PCD receive suboptimal management, which should include airway clearance, regular surveillance of pulmonary function and respiratory microbiology, and use of antibiotics targeted to pathogens. The PCD Foundation is developing a network of clinical centers, which should improve diagnosis and management of PCD.

Original languageEnglish
Pages (from-to)913-922
Number of pages10
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume188
Issue number8
DOIs
StatePublished - Oct 15 2013

Fingerprint

Kartagener Syndrome
Nose
Lung Diseases
Parturition
Ear Diseases
Lung
Bronchiectasis
Cilia
Middle Ear
Microbiology
Mechanics
Age of Onset
Cough
Cystic Fibrosis
Documentation
Nitric Oxide

Keywords

  • Genetics
  • Kartagener syndrome
  • Nasal nitric oxide
  • Newborn respiratory distress syndrome
  • Primary ciliary dyskinesia

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Primary ciliary dyskinesia : Recent advances in diagnostics, genetics, and characterization of clinical disease. / Knowles, Michael R.; Daniels, Leigh Anne; Davis, Stephanie; Zariwala, Maimoona A.; Leigh, Margaret W.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 188, No. 8, 15.10.2013, p. 913-922.

Research output: Contribution to journalArticle

Knowles, Michael R. ; Daniels, Leigh Anne ; Davis, Stephanie ; Zariwala, Maimoona A. ; Leigh, Margaret W. / Primary ciliary dyskinesia : Recent advances in diagnostics, genetics, and characterization of clinical disease. In: American Journal of Respiratory and Critical Care Medicine. 2013 ; Vol. 188, No. 8. pp. 913-922.
@article{1e800290782e4b5bbb9b56fb26741843,
title = "Primary ciliary dyskinesia: Recent advances in diagnostics, genetics, and characterization of clinical disease",
abstract = "Primary ciliary dyskinesia (PCD) is a genetically heterogeneous recessive disorder of motile cilia that leads to oto-sino-pulmonary diseases and organ laterality defects in approximately 50{\%} of cases. The estimated incidence of PCD is approximately 1 per 15,000 births, but the prevalence of PCD is difficult to determine, primarily because of limitations in diagnostic methods that focus on testing ciliary ultrastructure and function. Diagnostic capabilities have recently benefitted from (1) documentation of low nasal nitric oxide production in PCD and (2) discovery of biallelic mutations in multiple PCD-causing genes. The use of these complementary diagnostic approaches shows that at least 30{\%} of patients with PCD have normal ciliary ultrastructure. More accurate identification of patients with PCD has also allowed definition of a strong clinical phenotype, which includes neonatal respiratory distress in >80{\%} of cases, daily nasal congestion and wet cough starting soon after birth, and early development of recurrent/chronic middle-ear and sinus disease. Recent studies, using advanced imaging and pulmonary physiologic assessments, clearly demonstrate early onset of lung disease in PCD, with abnormal air flow mechanics by age 6-8 years that is similar to cystic fibrosis, and age-dependent onset of bronchiectasis. The treatment ofPCDis not standardized, and there are no validated PCD-specific therapies. Most patients with PCD receive suboptimal management, which should include airway clearance, regular surveillance of pulmonary function and respiratory microbiology, and use of antibiotics targeted to pathogens. The PCD Foundation is developing a network of clinical centers, which should improve diagnosis and management of PCD.",
keywords = "Genetics, Kartagener syndrome, Nasal nitric oxide, Newborn respiratory distress syndrome, Primary ciliary dyskinesia",
author = "Knowles, {Michael R.} and Daniels, {Leigh Anne} and Stephanie Davis and Zariwala, {Maimoona A.} and Leigh, {Margaret W.}",
year = "2013",
month = "10",
day = "15",
doi = "10.1164/rccm.201301-0059CI",
language = "English",
volume = "188",
pages = "913--922",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "8",

}

TY - JOUR

T1 - Primary ciliary dyskinesia

T2 - Recent advances in diagnostics, genetics, and characterization of clinical disease

AU - Knowles, Michael R.

AU - Daniels, Leigh Anne

AU - Davis, Stephanie

AU - Zariwala, Maimoona A.

AU - Leigh, Margaret W.

PY - 2013/10/15

Y1 - 2013/10/15

N2 - Primary ciliary dyskinesia (PCD) is a genetically heterogeneous recessive disorder of motile cilia that leads to oto-sino-pulmonary diseases and organ laterality defects in approximately 50% of cases. The estimated incidence of PCD is approximately 1 per 15,000 births, but the prevalence of PCD is difficult to determine, primarily because of limitations in diagnostic methods that focus on testing ciliary ultrastructure and function. Diagnostic capabilities have recently benefitted from (1) documentation of low nasal nitric oxide production in PCD and (2) discovery of biallelic mutations in multiple PCD-causing genes. The use of these complementary diagnostic approaches shows that at least 30% of patients with PCD have normal ciliary ultrastructure. More accurate identification of patients with PCD has also allowed definition of a strong clinical phenotype, which includes neonatal respiratory distress in >80% of cases, daily nasal congestion and wet cough starting soon after birth, and early development of recurrent/chronic middle-ear and sinus disease. Recent studies, using advanced imaging and pulmonary physiologic assessments, clearly demonstrate early onset of lung disease in PCD, with abnormal air flow mechanics by age 6-8 years that is similar to cystic fibrosis, and age-dependent onset of bronchiectasis. The treatment ofPCDis not standardized, and there are no validated PCD-specific therapies. Most patients with PCD receive suboptimal management, which should include airway clearance, regular surveillance of pulmonary function and respiratory microbiology, and use of antibiotics targeted to pathogens. The PCD Foundation is developing a network of clinical centers, which should improve diagnosis and management of PCD.

AB - Primary ciliary dyskinesia (PCD) is a genetically heterogeneous recessive disorder of motile cilia that leads to oto-sino-pulmonary diseases and organ laterality defects in approximately 50% of cases. The estimated incidence of PCD is approximately 1 per 15,000 births, but the prevalence of PCD is difficult to determine, primarily because of limitations in diagnostic methods that focus on testing ciliary ultrastructure and function. Diagnostic capabilities have recently benefitted from (1) documentation of low nasal nitric oxide production in PCD and (2) discovery of biallelic mutations in multiple PCD-causing genes. The use of these complementary diagnostic approaches shows that at least 30% of patients with PCD have normal ciliary ultrastructure. More accurate identification of patients with PCD has also allowed definition of a strong clinical phenotype, which includes neonatal respiratory distress in >80% of cases, daily nasal congestion and wet cough starting soon after birth, and early development of recurrent/chronic middle-ear and sinus disease. Recent studies, using advanced imaging and pulmonary physiologic assessments, clearly demonstrate early onset of lung disease in PCD, with abnormal air flow mechanics by age 6-8 years that is similar to cystic fibrosis, and age-dependent onset of bronchiectasis. The treatment ofPCDis not standardized, and there are no validated PCD-specific therapies. Most patients with PCD receive suboptimal management, which should include airway clearance, regular surveillance of pulmonary function and respiratory microbiology, and use of antibiotics targeted to pathogens. The PCD Foundation is developing a network of clinical centers, which should improve diagnosis and management of PCD.

KW - Genetics

KW - Kartagener syndrome

KW - Nasal nitric oxide

KW - Newborn respiratory distress syndrome

KW - Primary ciliary dyskinesia

UR - http://www.scopus.com/inward/record.url?scp=84886402463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886402463&partnerID=8YFLogxK

U2 - 10.1164/rccm.201301-0059CI

DO - 10.1164/rccm.201301-0059CI

M3 - Article

VL - 188

SP - 913

EP - 922

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 8

ER -